Medicus Pharma (MDCX): De‑Risking Drug Development to Capture a High‑Growth Market Opportunity

About this episode

Dr. Raza Bokhari discusses Medicus Pharma's strategy for acquiring mid-stage drug assets to reduce development risk.

Send us Fan Mail In this episode of WTR Small-Cap Spotlight, Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma (NASDAQ: MDCX), joins Tim Gerdeman and Robert Sassoon to walk through the company’s strategy and market focus. Dr. Bokhari explains how Medicus Pharma acquires mid‑stage drug assets with existing data, reducing development risk and positioning the company for potential partnerships with larger pharmaceutical players. The conversation highlights Medicus Pharma’s two lead ...

People in this episode

Hosts: Tim Gerdeman, Robert Sassoon

Guest: Dr. Raza Bokhari

Topics covered

• drug development
• pharmaceutical partnerships
• market strategy
• investment opportunities
• healthcare

Keywords

• Medicus Pharma
• drug development
• pharmaceutical
• investment
• market opportunity

Mentioned in this episode

Organizations: Medicus Pharma, NASDAQ

More episodes of WTR Small-Cap Spotlight

• Pineapple Financial (PAPL): AI Tools and Tokenization: How a Canadian Fintech Is Modernizing the Mortgage Brokerage Market · June 11, 2026 · 18 min
• eGain Corporation (EGAN): Turns Messy Enterprise Data into Trusted AI Answers · June 10, 2026 · 22 min
• Mobilicom (MOB): CEO Details Why Mobilicom’s Secure Comm System is the Heart and Soul of Drones and Robots · June 10, 2026 · 32 min
• ZJK Industrial (ZJK): Precision Parts at the Heart of AI, EVs, and High-Tech Manufacturing · June 9, 2026 · 22 min
• LiveOne (LVO): The AT&T Deal, B2B Streaming Strategy, and Why Every Platform Needs an Audio Network · June 4, 2026 · 37 min
• CIRCULAR ECONOMY: Investing in SAF, CCUS and Waste-to-Value (PART 2 – CCUS) · June 4, 2026 · 52 min